‘100 Million Cell Challenge’ to boost single cell genomics research
Scale Biosciences (Scale Bio) has launched the ‘100 Million Cell Challenge’, which hopes to push the boundaries of single-cell genomics research, in collaboration with Ultima Genomics and NVIDIA.
The programme calls on researchers worldwide to submit proposals for large-scale single cell projects, with the goal of collectively analysing 100 million cells or more across diverse biological systems and research areas.
Giovanna Prout, President and CEO of Scale Bio, said: “By bringing together researchers from various disciplines and providing them with advanced technology from Scale Bio and our collaborators, we aim to catalyse new discoveries that will shape the future of precision medicine, further our understanding of complex biological systems, and fuel the explosion of generative AI that is being leveraged in biology.”
Key features of the challenge
- Minimum project size of one million cells, with no maximum limit
- Collaboration with industry-leading partners for sequencing and data analysis services
- Substantially subsidised costs for library preparation and sequencing services
“Effectively training foundation models requires an immense amount of data. The dramatic increase in high-resolution single cell experiments from this project will help significantly impact translational research,” said George Vacek, Global Head of Genomics Alliances at NVIDIA.
Researchers interested in participating can submit their project proposals from 8 August to 15 October 2024. Selected projects will be announced at the American Society of Human Genetics (ASHG) Annual Meeting in November 2024.
Dr Ronan Chaligne, Director, Single Cell Innovation Lab at MSK Cancer Center, commented: “The ability to analyse millions of cells in a single experiment is a game-changer. It will allow us to detect rare cell populations, understand cellular heterogeneity at an unprecedented level, and potentially uncover entirely new biological phenomena. This Challenge will accelerate our understanding of complex diseases and lead to novel therapeutic approaches.”
Diana Spencer, Senior Digital Content Editor, DDW
